SymBio Pharmaceuticals: Accelerating Growth Strategy
Edison | Nov 30, 2015 06:24AM ET
Accelerating its growth strategy
SymBio (WA:SYM) recently acquired the exclusive rights to develop and market IONSYS, a fentanyl iontophoretic transdermal system for acute post-operative pain, in Japan. Treakisym is nearing a decision on additional indications and development is again moving ahead for rigosertib. With a third product in its development portfolio, we believe SymBio has the confidence to accelerate its in-licensing programme on its quest to become the pharmaceutical partner of choice in Asia-Pacific.
SymBio adds pain management to its portfolio
SymBio recently acquired exclusive rights to develop and market IONSYS, a patient-controlled fentanyl iontophoretic transdermal system in Japan, for $10m upfront plus undisclosed milestones and royalties. We believe IONSYS has a high probability of success – low regulatory risk, a large target market, positive clinical experience and clear competitive advantages over existing patient-controlled analgesia for post-operative pain based on a conventional electrical infusion pump. IONSYS diversifies, and in our view, de-risks SymBio’s development portfolio.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.